Breaking News From Pharma & Bio Ingredients Subscribe via RSS Subscribe via RSS



Watson To Divest Injectable Manufacturing Facility


Posted on 2006-03-30 08:59:00



As part of an ongoing effort to optimize its manufacturing operations, Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today announced its plan to divest its injectable manufacturing facility located in Phoenix, Arizona.

The Phoenix facility currently manufactures fifteen products, including several manufactured for third parties. Over the next twelve months, the Company plans to establish contract manufacturing agreements for key products with third-party suppliers or with a new owner of the facility. If a suitable purchaser is not identified, Watson expects to close the facility by the end of the second quarter in 2007.

"I wish to thank the entire employee team at Phoenix for their focus and commitment since becoming part of our organization in 2000, following our acquisition of Schein Pharmaceutical," began Dr. Allen Chao, Watson's chairman and chief executive officer. "Over the past several years, the Phoenix team has worked diligently to reestablish production consistent with the commitments of a consent decree. In 2004, the consent decree was vacated, providing further acknowledgement of the collective efforts made by the dedicated facility team."

The Phoenix facility is the only sterile injectable manufacturing operation owned by Watson. The facility was acquired in 2000 as part of the company's acquisition of Schein Pharmaceutical, Inc. and employs approximately 236 employees.


NEWS ARCHIVES

2008

2007

2006

2005

2004

NEWSLETTER SIGNUP